SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as community members rally around its Bitcoin-native status and potential to outperform other meme coins. Discussion highlights its fair launch, strong community, and the belief that it will lead the current cycle. Many see $DOG.X as more than just a meme, but a movement that strengthens the Bitcoin network.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK.X is trending as Cocky Wings LLC prepares to launch, merging meme culture with a real-world food business. The community is focused on the launch of their food truck and the potential for real-world revenue driving buybacks. Many highlight the project's focus on utility and real-world asset integration within the crypto space.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK.X is trending as traders discuss its potential for a rally, while also navigating volatility and comparing it to other meme coins like DOGE.X and SHIB.X. Community members are actively debating entry points, bag sizes, and the possibility of an upcoming "midnight run," amidst speculation about market manipulation.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a deal to sell land for up to $28.74M, potentially increasing its NAV to $14.83 per share. The community is discussing the stock's low float, potential for a short squeeze, and possible breakout towards the $20-$25 range, with some comparing it to other recent low-float runners.

YUPFUN is a Solana-based meme and DeFi project that fuses viral meme culture with real decentralized finance utility. It aims to create a fun, community-driven ecosystem where users can trade, stake, and bridge tokens seamlessly across multiple liquidity pools and decentralized exchanges (DEXs) like BitStorage.finance Raydium, Orca, Meteora, PumpSwap, MintMe.com. YUPFUN isn't just about memes — it's about empowering the community with real ownership through fair launch mechanics, liquidity incentives, and cross-chain accessibility. The project also promotes creative engagement by encouraging users to create and share memes, art, and participate in community-driven events to grow the YUPFUN brand. With no VC backing, no private sales, and no hidden agendas, YUPFUN represents a true decentralized, permissionless movement blending entertainment with real blockchain functionality.

YUPFUN Token

YUPFUN.X is trending as social media buzz highlights the project's unique qualities and potential for virality. Community members are expressing strong bullish sentiment, citing positive chart indicators. The overall tone suggests excitement about YUPFUN's potential impact.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending following positive Phase 2 trial data for their uveal melanoma treatment, darovasertib, and crizotinib combination, as well as a successful FDA meeting regarding accelerated approval. The community is discussing the potential for this therapy to transform cancer care and address unmet medical needs, especially given upcoming catalysts and clinical data updates. Analysts are also weighing in with price target increases.

Martin Marietta Materials, Inc. is a natural resource-based building materials company, which engages in the provision of aggregates including crushed stone, sand, and gravel through its network of quarries and distribution yards. It operates through the East Group and West Group segments. The East Group segment offers aggregates and asphalt products. The West Group segment focuses on aggregates, cement, downstream products, and paving services. The company was founded on November 12, 1993 and is headquartered in Raleigh, NC.

Martin Marietta Materials, Inc.

Martin Marietta Materials is trending as investors discuss its peer valuations relative to smaller companies in the building materials sector, like $CAPS. Additionally, recent analyst target price adjustments and strong earnings reports are fueling interest. A dividend increase has also drawn attention amid market volatility.

Vulcan Materials Co. engages in the production of construction aggregates. It operates through the following segments: Aggregates, Asphalt, and Concrete. The Aggregates segment produces and sells aggregates and related products and services. The Asphalt segment relates to the production and selling of asphalt mix in Arizona, California, New Mexico, Tennessee, and Texas. The Concrete segment refers to the production and selling of ready-mixed concrete in California, Maryland, and Virginia in addition to the U.S. Virgin Islands and Washington D.C. The company was founded in 1909 and is headquartered in Birmingham, AL.

Vulcan Materials Co

Vulcan Materials' Q2 earnings results and future growth potential are driving community discussion. While some analysts are adjusting price targets, others highlight the company's strong market position and potential to benefit from infrastructure spending. A microcap stock, CAPS, is also being discussed as a peer comparison within the building materials sector, especially in terms of revenue growth.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

Roche Holdings AG ADR

Roche Holdings is trending due to positive clinical trial data for Vabysmo in treating nAMD, with discussions focusing on its potential to extend dosing intervals and improve vision outcomes.  Community members are also actively discussing a potential bidding war with AbbVie for assets related to myeloid disease, sparked by Verona Pharma's recent trial results. Additionally, some shareholders express frustration and call for payouts related to the LumiraDx acquisition, alleging undervalued assets and mishandled shareholder interests.

Sapien is an open protocol for sourcing verified human knowledge at scale. Its network of millions of contributors spans more than 100 countries, ranging from doctors and engineers to artists and students. Together they produce high-quality AI training data, validated through Sapien’s onchain Proof of Quality system. This ensures enterprises and AI developers can access trusted, human-in-the-loop data while transforming fragmented online work into a sustainable, reputation-based profession. Incentives across the network are powered by the $SAPIEN token, an ERC-20 asset on Base.

Sapien

Sapien is trending as community members discuss its potential for significant gains and speculate on price movements, with some setting ambitious targets. Conversations also address whether the token is a legitimate opportunity or a potential scam, with a focus on its chart setup. The broader discussion includes the potential for Sapien to reach new all-time highs, especially with mentions of AI and data control.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?

Investors need to pay close attention to Esperion Therapeutics stock based on the movements in the options market lately.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Equity

Shares of Esperion Therapeutics (ESPR) surged over 12% on Tuesday, marking their best session since early December, as the pharmaceutical company posted a strong fourth-quarter report that exceeded expectations.Esperion reported a quarterly loss of $0.11 per share, better than a consensus estimate of a $0.16 loss.&nbsp;Revenue came in at $69.1 million, surpassing expectations of $61.58 million.&nbsp;CEO Sheldon Koenig said Esperion expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe, as well as global expansion into key markets like Japan.Effective Jan. 29, 2025, the U.S. Department of Defense added Esperion’s NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) to its Uniform Formulary as preferred agents, covering nine million lives.&nbsp;The company also expanded its prescriber base, now reaching over 25,000 healthcare practitioners — a 10% increase from Q3.Esperion has initiated the development of two triple-combination products in the U.S., incorporating bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin.&nbsp;The company believes these formulations could offer low-density lipoprotein cholesterol (LDL-C) reductions exceeding 60%, positioning them as competitive alternatives to existing and emerging injectable and oral cholesterol-lowering therapies.Esperion said its Japanese partner, Otsuka Pharmaceutical Co., Ltd., has submitted a New Drug Application for bempedoic acid in the Asian country for the treatment of hypercholesterolemia and familial hypercholesterolemia.&nbsp;Otsuka anticipates approval and National Health Insurance pricing in the second half of 2025.H.C. Wainwright &amp; Co. reportedly maintained its $16.00 price target on Esperion, implying an 800% upside from current levels, according to Dow Jones newswires.On Stocktwits, sentiment remained ‘extremely bullish’ as message volume spiked 13% in the 24 hours to Tuesday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ESPR_sentiment_and_message_volume_as_on_March_4_4d838f95e8.png" alt="ESPR sentiment and message volume as on March 4.png" width="1316" height="316"><figcaption>ESPR sentiment and message volume as on March 4 | source: Stocktwits</figcaption></figure>One user speculated on the potential for growing royalties from international markets like Japan, Australia, and Israel.<stembedurl>https://stocktwits.com/theDeathStar/message/606790322</stembedurl>Another user suggested Otsuka could expand its partnership or buyout Esperion — rather than Daiichi Sankyo — on the back of its $20 billion cash reserves and stated plans for acquisitions this year.<stembedurl>https://stocktwits.com/djohnson591/message/606725247</stembedurl>Esperion originally signed a licensing agreement with Daiichi Sankyo Europe in 2019, granting exclusive rights to commercialize bempedoic acid products in the European Economic Area and Switzerland.<a href="https://stocktwits.com/symbol/ESPR">Esperion shares</a> remain down more than 20% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets.

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024...

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESPR News

ESPR Esperion Therapeutics Inc.